Rozanolixizumab

What It Is

Rozanolixizumab is the third FcRn blocker to reach the market and the one that made subcutaneous, cycle-based dosing the class's convenience story. It shares the same core mechanism as efgartigimod and nipocalimab - occupy the neonatal Fc receptor so the body's own IgG, including the harmful autoantibodies, is degraded instead of rescued and recycled - but it stakes out its own niche in three ways: molecular format, route, and the breadth of its myasthenia label. Where efgartigimod is an isolated, engineered Fc fragment and nipocalimab is an aglycosylated full-length IgG1, rozanolixizumab is a humanized full-length IgG4 monoclonal antibody that binds human FcRn with very high affinity and accelerates the catabolism of circulating IgG, driving total IgG down by roughly 70-80% at therapeutic doses while leaving IgM, IgA, complement, and albumin essentially untouched. UCB developed it as UCB7665 and designed it for subcutaneous delivery: a rapid manual push or an on-body infusion device rather than a hospital IV line, given as weekly infusions in short cycles that are repeated according to how a patient responds - a 'reduce and re-treat' rhythm closer to efgartigimod's cyclic approach than to nipocalimab's continuous maintenance dosing. The defining feature of its FDA approval is breadth of serotype coverage. When Rystiggo was cleared on June 27, 2023, it became the first and, at the time, only therapy approved to treat generalized myasthenia gravis in both anti-AChR-antibody-positive and anti-MuSK-antibody-positive adults - beating both efgartigimod (initially approved only for AChR-positive disease) and nipocalimab to explicit MuSK coverage. Approval rested on MycarinG (NCT03971422), a Phase 3, randomized, double-blind, placebo-controlled, adaptive study in which adults with gMG received once-weekly subcutaneous rozanolixizumab (7 mg/kg or 10 mg/kg) or placebo for six weeks; both doses produced statistically significant improvements in the MG-ADL daily-living score versus placebo, with a dedicated subgroup analysis confirming benefit in the harder-to-treat MuSK-positive population, and the results were published in The Lancet Neurology in 2023. Long-term open-label extensions (MG0004 and MG0007) supported the safety and durability of repeated cyclical dosing. Beyond myasthenia gravis, rozanolixizumab is a useful lesson in the limits of the FcRn mechanism as much as its promise. In chronic inflammatory demyelinating polyneuropathy (CIDP), the Phase 2a CIDP01 study and its extension found rozanolixizumab well tolerated but without clinically meaningful efficacy, and UCB elected not to advance it to a Phase 3 CIDP program - a notable contrast with efgartigimod, which is approved in CIDP, and a reminder that lowering IgG does not help every antibody-associated disease equally. Development has continued in other directions: a Phase 3 program in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), earlier work in primary immune thrombocytopenia (ITP), and interest in other IgG-driven conditions. The most common adverse effects are headache, infections, and administration-related reactions, consistent with the FcRn class's central trade-off - deliberately lowering IgG increases susceptibility to infection. Taken together, rozanolixizumab rounds out the first generation of FcRn antagonists as the subcutaneous, broad-serotype myasthenia option, and it is routinely compared head-to-head with efgartigimod and nipocalimab on format (full IgG4 antibody vs Fc fragment vs aglycosylated IgG1), route (subcutaneous vs intravenous), and dosing (cyclic vs maintenance).

Regulatory Status

Why Researchers Study It

Rozanolixizumab matters to researchers as the third FcRn blocker to reach the market and the one that anchors two comparisons the class keeps returning to: route and serotype breadth. It is a humanized full-length IgG4 antibody delivered subcutaneously in short weekly cycles, which sets it against efgartigimod's Fc fragment and nipocalimab's aglycosylated IgG1, and against their intravenous or maintenance regimens - letting researchers study how antibody format and delivery route shape the depth, speed, and durability of IgG lowering and, ultimately, patient convenience. Its FDA approval covering both AChR- and MuSK-antibody-positive myasthenia gravis made it the first drug approved across both serotypes, and its MycarinG MuSK subgroup analysis is one of the cleaner controlled datasets in that hard-to-treat population. Rozanolixizumab is also scientifically valuable as a negative result: in CIDP it was well tolerated but did not deliver meaningful efficacy and was not advanced to Phase 3, a direct contrast with efgartigimod's success in CIDP that helps define which IgG-driven diseases actually respond to lowering the antibody pool. Its continued development in MOGAD and immune thrombocytopenia extends that question to other autoantibody conditions. For drug developers, it is a reference point for subcutaneous FcRn blockade and on-body delivery, and for clinicians it frames the practical choice between cyclic subcutaneous and continuous intravenous IgG-lowering therapy.

Proposed Mechanisms

• Humanized full-length IgG4 monoclonal antibody that binds the neonatal Fc receptor (FcRn) with very high affinity - a whole antibody rather than the isolated Fc fragment used by efgartigimod, and not a small synthetic peptide
• By occupying FcRn, it blocks FcRn-mediated recycling of endogenous IgG; IgG that would normally be rescued from the endosome and returned to the blood is instead routed to the lysosome and degraded, accelerating IgG catabolism and lowering total circulating IgG by roughly 70-80% at therapeutic doses
• Selectively reduces IgG - including pathogenic autoantibodies driving diseases such as myasthenia gravis - without lowering IgM, IgA, complement, or albumin, distinguishing it from broad immunosuppression, plasma exchange, and IVIg
• Built on an IgG4 backbone rather than IgG1, and used purely as an FcRn-blocking agent, so its therapeutic action is receptor occupancy rather than immune effector recruitment
• Delivered as a rapid subcutaneous infusion (including via an on-body delivery device) in once-weekly cycles that are repeated based on clinical response - a cyclic 'reduce and re-treat' regimen rather than continuous maintenance dosing
• Because FcRn also transports IgG across the placenta and salvages IgG throughout the body, blocking it lowers the systemic IgG pool that sustains autoantibody-mediated disease - the shared rationale of the FcRn antagonist class

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Rozanolixizumab compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] UCB announces U.S. FDA approval of RYSTIGGO (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis - UCB, June 2023 PubMed
2. [2] FDA Approves Rozanolixizumab-noli for Generalized Myasthenia Gravis - AJMC PubMed
3. [3] Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study - The Lancet Neurology, 2023 PubMed
4. [4] Efficacy and safety of rozanolixizumab in MuSK-antibody-positive generalised myasthenia gravis: a MycarinG subgroup analysis PubMed
5. [5] Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP01): a phase 2a trial and open-label extension - PubMed PubMed
6. [6] Rozanolixizumab (UCB7665): identifiers and mechanism - DrugBank DB14919 (CAS 1584645-37-3, humanized IgG4 anti-FcRn) PubMed
7. [7] Rozanolixizumab - Wikipedia (overview, humanized IgG4 anti-FcRn antibody, Rystiggo) PubMed

Related Peptides